Post by Biogen

1,294,902 followers

From breakthrough science to meaningful conversations, our Chief Medical Officer, Daniel Quirk, MD, MPH, MBA, takes you on the grounds of #ATCBoston2026, where we shared data on our investigational therapy designed to target CD-38 cells in antibody-mediated rejection (AMR) and microvascular inflammation (MVI) and research in rare complement-driven kidney disease.      Learn about our advancements in immune-mediated kidney disease: https://lnkd.in/g59BwFgq

Post content

Video Content